Eli Lilly and NVIDIA Unveil Pharma’s Next-Gen AI Supercomputer

Eli Lilly and Company has announced a landmark collaboration with NVIDIA to build what they describe as the most powerful artificial intelligence supercomputer ever operated by a pharmaceutical company. The new infrastructure, based on NVIDIA’s DGX SuperPOD design and powered by over one thousand B300 GPUs, will form the backbone of Lilly’s new AI factory.

This supercomputer will accelerate the discovery and delivery of medicines by training models on millions of experiments, exploring vast chemical and biological spaces, and optimising production and manufacturing processes. It will also enhance medical imaging, support digital twins for manufacturing sites, and power enterprise-wide AI assistants.

Lilly emphasises that artificial intelligence is no longer just a tool but a scientific collaborator built into every step of its research workflow. The company also highlights that the system will run entirely on renewable energy and utilise existing chilled-water cooling systems as part of its sustainability commitments.

The partnership signals a major shift in how pharmaceutical research integrates large-scale computing, blending deep learning with scientific innovation to accelerate therapeutic discovery.